Meeting
2023 ASCO Genitourinary Cancers Symposium
The prognostic value of ECOG performance status on overall survival among patients with metastatic prostate cancer: A systematic review of the literature and meta-analysis.
Authors
Jonathan Assayag
Pfizer Inc, New York, NY
Jonathan Assayag , Chai Kim , Jennifer Webster , Haitao Chu
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Poster Session B: Prostate Cancer and Urothelial Carcinoma
Track
Urothelial Carcinoma,Prostate Cancer - Advanced
Sub Track
Symptoms, Toxicities, Patient-Reported Outcomes, and Whole-Person Care
Citation
J Clin Oncol 41, 2023 (suppl 6; abstr 124)
DOI
10.1200/JCO.2023.41.6_suppl.124
Abstract #
124
Poster Bd #
E11
Abstract Disclosures
Similar Posters
Poster
2023 ASCO Annual Meeting
Real-world experience with tumor treating fields (TTFields) in newly diagnosed glioblastoma: A survival meta-analysis with systematic review.
First Author: Matthew T. Ballo
Poster
2024 ASCO Genitourinary Cancers Symposium
Real-world (RW) survival and outcomes with androgen receptor pathway inhibitor (ARPI) –doublet therapy in patients (pts) with de novo metastatic castration-sensitive prostate cancer (mCSPC).
First Author: Joshua Parrish
Poster
2024 ASCO Genitourinary Cancers Symposium
First-line PARP inhibitors (PARPi) with androgen receptor pathway inhibitors (ARPi) in metastatic castration-resistant prostate cancer (mCRPC): A systematic review and meta-analysis.
First Author: Muhammad Ali Khan
Poster
2023 ASCO Annual Meeting
A systematic review and meta-analysis of intrathecal versus alternate routes of delivery for HER2-targeted therapies in patients with HER2+ breast cancer leptomeningeal metastases.
First Author: Anna-Maria Lazaratos